Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
02 Sep 2014 Validation of Genome-Driven Integrated Classification of Breast Cancer Breast cancer - Translational research
01 Sep 2014 Adjuvant Irinotecan Shows Promise for Subset of Stage III Colon Cancer Patients Translational research - Gastrointestinal cancers - Anticancer agents & Biologic therapy
27 Aug 2014 Discovery of Novel Mechanism by Which Senescence is Evaded in Tumour Cells Translational research
26 Aug 2014 The Mutational Burden of Acral Melanoma Translational research - Melanoma
25 Aug 2014 High Concordance Between EGFR Mutations From ctDNA and Tumour Tissue in NSCLC Personalised medicine - Translational research - Lung and other thoracic tumours
21 Aug 2014 Researchers Develop Web-Based App to Predict Glioma Mutations Personalised medicine - Central nervous system malignancies
20 Aug 2014 Older Patients With Limited Life Expectancy Still Receiving Cancer Screenings Cancer prevention
19 Aug 2014 FDA Approves Bevacizumab to Treat Patients with Persistent, Recurrent or Metastatic Cervical Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
18 Aug 2014 Molecular Classification of 12 Cancer Types Translational research
13 Aug 2014 FDA Approves First Non-invasive DNA Screening Test for Colorectal Cancer Cancer prevention - Gastrointestinal cancers
31 Jul 2014 European Medicines Agency Recommends Granting a Marketing Authorisation for Biosimilar Filgrastim Palliative and supportive care
30 Jul 2014 European Medicines Agency Recommends Granting a Marketing Authorisation for Ibrutinib Haematologic malignancies - Anticancer agents & Biologic therapy
29 Jul 2014 European Medicines Agency Recommends Extension of Indications for Denosumab Palliative and supportive care
28 Jul 2014 European Medicines Agency Recommends Approval of Idelalisib Haematologic malignancies - Anticancer agents & Biologic therapy
24 Jul 2014 FDA Approves PI3K Inhibitor, Idelalisib for Treatment of Relapsed CLL, Follicular Lymphoma and SLL Haematologic malignancies - Anticancer agents & Biologic therapy